therapiAI, a leading AI pharmaceutical company, announced today the launch of the world’s first AI Agent dedicated to Antibody-Drug Conjugates (ADCs). This technology significantly compresses the traditional 2-3 year R&D exploration phase. By following the AI Agent’s recommendations, researchers can avoid unnecessary experimental detours. The system predicts the optimal ranking of antibody, linker, and payload combinations, drastically reducing trial-and-error costs for pharmaceutical CDMOs. therapiAI is already in talks with several international CDMOs; with this technological breakthrough, the company is emerging as a highly spotlighted leader in the rising wave of ADC drug development.
Hailed as the “magic bullets” of cancer therapy, Antibody-Drug Conjugates (ADCs) utilize a “monoclonal antibody-linker-small molecule payload” structure to precisely deliver cytotoxic agents into tumor cells, representing one of the most significant breakthroughs in oncology in recent years.
The market for ADCs is expanding rapidly. Research and Markets estimates the sector will exceed $24.8 billion by 2028, while Morgan Stanley remains even more optimistic, projecting long-term potential reaching up to $140 billion.
In recent years, ADCs have emerged as one of the hottest sectors in the global biotechnology landscape. In 2023 alone, the total value of related M&A and licensing deals approached $100 billion—a threefold increase year-over-year. Notable transactions include Pfizer’s $43 billion acquisition of Seagen and the $22 billion strategic collaboration between Daiichi Sankyo and Merck. This momentum has carried into 2025, with Japan’s Taiho Pharmaceutical and Denmark’s Genmab both acquiring ADC startups.
Currently, 15 ADCs have been approved for market. McKinsey projects that the top three ADC drugs alone will generate a combined $17 billion in revenue by 2028. Furthermore, with over 400 ADC projects currently in development globally—approximately 200 of which have entered clinical trials—it is clear that this wave of innovation is only just beginning.
However, despite the massive market potential, the R&D and manufacturing of ADCs remain highly complex. Experts often must rely on past experience to manually sift through mountains of literature, patents, and clinical data to design experiments—a process that is both time-consuming and costly.This not only raises the barriers to new drug development but also risks causing pharmaceutical companies to miss critical market opportunities.
TherapiAI’s newly launched ADC AI Agent offers a novel solution to these challenges. By simply asking questions in natural language, biotech experts can leverage the system to automatically integrate ADC knowledge databases and predict the optimal combinations of antibodies, linkers, and payloads.
Beyond shortening exploration timelines, the ADC AI Agent delivers actionable insights—such as identifying which linkers enhance drug solubility or which payloads exhibit lower off-target toxicity—enabling researchers to rapidly focus on the most promising development paths.
Furthermore, TherapiAI’s ADC AI Agent can predict potential manufacturing parameters, helping pharmaceutical companies and CDMOs significantly reduce ineffective trial-and-error and channel resources directly into the solutions with the highest probability of success. Leveraging this technological advantage, TherapiAI empowers its partners to seize critical opportunities in the ADC market with greater speed and lower costs.
Michael Han, Founder of TherapiAI, stated: “The costs associated with ADC process development and commercialization are exorbitant, often exceeding millions of dollars. Through this world-first AI Agent, we aim to empower CDMOs to drastically shorten timelines for drug discovery and process optimization—effectively transforming R&D costs into revenue, accelerating time-to-market, and expanding value creation across the entire pharmaceutical industry.”
Currently, TherapiAI has garnered significant attention from top-tier international pharmaceutical companies and CDMOs, with discussions underway across key Asian markets.
Looking ahead, TherapiAI is dedicated to deploying AI at the forefront of pharmaceutical manufacturing, establishing itself as the most trusted decision-making engine for CDMOs. With ADCs recognized as the next multi-billion-dollar frontier in cancer therapy, TherapiAI is poised to be a crucial catalyst in this wave, accelerating the delivery of life-changing treatment options to patients worldwide.
